Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,619 | 265 | 1,332 |
| Samples | 791 | 156 | 623 |
| Peptides | 632 | 118 | 526 |
Function
PIK3C2B · Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta
The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. The PI3-kinase activity of this protein is sensitive to low nanomolar levels of the inhibitor wortmanin. The C2 domain of this protein was shown to bind phospholipids but not Ca2+, which suggests that this enzyme may function in a calcium-independent manner. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 593 amino-acid changes on canonical ENST00000367187 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PIK3C2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PIK3C2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 33/612 5% |
| Melanoma | 6/210 3% | 76/1899 4% |
| Colorectal Carcinoma | 36/143 25% | 89/3239 3% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 25/810 3% |
| Bladder Carcinoma | 3/58 5% | 30/956 3% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 37/1390 3% |
| Cervical Carcinoma | 2/35 6% | 11/422 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Gastric Carcinoma | 3/74 4% | 44/1809 2% |
| Ewings Sarcoma | 7/63 11% | 1/262 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Hodgkins Lymphoma | 1/16 6% | 2/122 2% |
| Germ Cell Tumour | 0/25 0% | 4/169 2% |
| Other Solid Cancers | 2/94 2% | 28/1515 2% |
| Neuroendocrine Tumour | 11/154 7% | 2/577 0% |
| Ovarian Carcinoma | 10/109 9% | 9/998 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 10/752 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Biliary Tract Carcinoma | 2/54 4% | 13/950 1% |
| Plasma Cell Myeloma | 4/44 9% | 1/305 0% |
| Mesothelioma | 1/62 2% | 2/165 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 20/1592 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 31/2550 1% |
| Head and Neck Carcinoma | 1/85 1% | 19/1574 1% |
| Breast Carcinoma | 10/144 7% | 31/3264 1% |
| Glioma | 0/52 0% | 26/2127 1% |
Mutation Distribution
Where PIK3C2B is mutated · all tissues, split by cell line vs tissue
How many mutations in PIK3C2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,619 mutations in PIK3C2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|